ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma (vol 9, pg 396, 2018)

被引：0
|
作者：
Ojha, R.
Leli, N. M.
Onorati, A.
Piao, S.
Verginadis, I. I.
Tameire, F.
Chu, Charleen T.
机构：
来源：
CANCER DISCOVERY | 2019年 / 9卷 / 07期
关键词：
D O I：
10.1158/2159-8290.CD-19-0632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：981 / 981
页数：1
相关论文
共 37 条
  • [31] sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (vol 532, pg 250, 2016)
    Kaur, Amanpreet
    Webster, Marie R.
    Marchbank, Katie
    Behera, Reeti
    Ndoye, Abibatou
    Kugel, Curtis H.
    Dang, Vanessa M.
    Appleton, Jessica
    O'Connell, Michael P.
    Cheng, Phil
    Valiga, Alexander A.
    Morissette, Rachel
    McDonnell, Nazli B.
    Ferrucci, Luigi
    Kossenkov, Andrew V.
    Meeth, Katrina
    Tang, Hsin-Yao
    Yin, Xiangfan
    Wood, William H.
    Lehrmann, Elin
    Becker, Kevin G.
    Flaherty, Keith T.
    Frederick, Dennie T.
    Wargo, Jennifer A.
    Cooper, Zachary A.
    Tetzlaff, Michael T.
    Hudgens, Courtney
    Aird, Katherine M.
    Zhang, Rugang
    Xu, Xiaowei
    Liu, Qin
    Bartlett, Edmund
    Karakousis, Giorgos
    Eroglu, Zeynep
    Lo, Roger S.
    Chan, Matthew
    Menzies, Alexander M.
    Long, Georgina V.
    Johnson, Douglas B.
    Sosman, Jeffrey
    Schilling, Bastian
    Schadendorf, Dirk
    Speicher, David W.
    Bosenberg, Marcus
    Ribas, Antoni
    Weeraratna, Ashani T.
    NATURE, 2016, 537 (7619) : 254 - 254
  • [32] Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report (vol 11, pg 557, 2016)
    Dooley, Andrew J.
    Gupta, Avinash
    Middleton, Mark R.
    TARGETED ONCOLOGY, 2017, 12 (03) : 385 - 385
  • [33] Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS) (vol 152, pg 116, 2021)
    Gogas, Helen
    Dummer, Reinhard
    Ascierto, Paolo A.
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    Sileni, Vanna Chiarion
    Dutriaux, Caroline
    Yamazaki, Naoya
    Loquai, Carmen
    Queirolo, Paola
    de Willem, Groot J.
    Sellier, Abir T.
    Suissa, Jeanne
    Murris, Juliette
    Gollerkeri, Ashwin
    Robert, Caroline
    Flaherty, Keith T.
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 287 - 288
  • [34] Primary cross-resistance to BRAFV600E-, MEK1/2-and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
    Penna, Ilaria
    Molla, Alessandra
    Grazia, Giulia
    Cleris, Loredana
    Nicolini, Gabriella
    Perrone, Federica
    Picciani, Benedetta
    Del Vecchio, Michele
    de Braud, Filippo
    Mortarini, Roberta
    Anichini, Andrea
    ONCOTARGET, 2016, 7 (04) : 3947 - 3965
  • [35] RETRACTION: Retraction: EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines (Retraction of Vol 7, Pg 1627, 2016)
    不详
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10) : 2326 - 2326
  • [36] Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial (vol 5, pg 187, 2018)
    Ascierto, P. A.
    Long, G., V
    Robert, C.
    JAMA ONCOLOGY, 2019, 5 (02) : 271 - 271
  • [37] Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2 (vol 9, pg 1282, 2020)
    Alicea, G. M.
    Rebecca, V. W.
    Goldman, A. R.
    Fane, M. E.
    Douglass, S. M.
    Behera, R.
    CANCER DISCOVERY, 2023, 13 (06) : 1498 - 1498
1234